The target action date for Rexulti in combination with sertraline to treat patients with post-traumatic stress disorder, ...

Lundbeck’s drug portfolio faces patent expirations but shows growth potential. Find out why HLBBF stock could see upside with ...

Amylyx Pharmaceuticals has named Dan Monahan as chief commercial officer, positioning an exec who led the U.S.

In one study, the company’s drug eased the agitation for Alzheimer’s patients. In a different study, there wasn’t a ...

With two earlier trials meeting their primary endpoints, Axsome claimed it has the data to support a filing for FDA approval ...

This training course will guide you through the principles of safe prescribing and demonstrate how to complete the National Standard Medication Charts correctly. The course comprises of 5 modules: ...

Wells Fargo says that while the ADVANCE-2 miss makes the regulatory path less certain, the totality of the data supports approval for Axsome ...

Axsome Therapeutics said on Monday it would seek marketing approval next year for its oral drug to treat agitation in patients with Alzheimer's disease, after it succeeded in three out of four ...

The drug did not show statistical significance ... cognitive and behavioral symptoms such as agitation and aggression. Rexulti contains the FDA's harshest "black-box" warning for increased risk ...

A recent survey reveals a significant decline in teen drug and alcohol use since 2017, reaching its lowest point in 2024. Researchers attribute this drop to pandemic lockdowns disrupting social ...

Join us in sending love this Valentine's Day with Cupid Crew. Help Register Login Login Hi, %{firstName}% Hi, %{firstName}% Games Car rental Managing prescription medications can be a challenge for ...

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Brexpiprazole (Rexulti, Rxulti) is a quinolinone derivative, acts as ...